Pavlu J et al. - In a study to explore ocular complications in imatinib-treated Ph+ chronic myeloid leukemia (CML) pts, it seems that side effects consisted of a wide spectrum of adverse effects ranging from periobital oedema to serious adverse events such as glaucoma Methods
Imatinib mesylate is a selective inhibitor of the bcr/abl, c-kit and PDGF receptor tyrosine kinases
Its ocular toxicity is little known with mild periorbital oedema being the most commonly reported side effect
Results
Side effects consisted of a wide spectrum of adverse effects ranging from periobital oedema to serious adverse events such as glaucoma
See all
